ADHD and PMDD - What we know, what the evidence shows, and what it means
Summary: Women with ADHD are significantly more likely to experience severe premenstrual mood symptoms, including PMDD. Research suggests clear biological overlap between the two conditions, and understanding this connection can help women recognise patterns, manage symptoms, and seek effective support.
What is ADHD and PMDD?
- ADHD (Attention-Deficit/Hyperactivity Disorder) is a brain-based condition that affects focus, attention, impulsivity, and emotional regulation. In women, ADHD often presents as inattention and internalised symptoms, and many remain undiagnosed until adulthood.
- PMDD (Premenstrual Dysphoric Disorder) is a severe form of premenstrual mood disturbance. Symptoms include intense irritability, low mood, anxiety, and physical discomfort in the one to two weeks before a period, resolving once bleeding starts. Unlike common PMS, PMDD significantly impacts daily life and functioning.
Takeaway: ADHD affects emotional regulation; PMDD affects sensitivity to hormonal shifts. Together, they can intensify premenstrual symptoms.
Here's what the research shows
- In the general population, PMDD affects around 3–8% of women.
- Among women with ADHD, 20-45% report PMDD-like symptoms, depending on study methods.
- One self-report study found 45.5% of women with ADHD met provisional PMDD criteria (1).
- A large community survey found 31.4% of women with a formal ADHD diagnosis and 41.1% of those meeting ADHD symptom criteria met provisional PMDD criteria, compared to 9.8% of women without ADHD (2).
- Women with ADHD and PMDD often report worsening of ADHD symptoms (inattention, impulsivity, emotional regulation) during the luteal (pre-period) phase (3).
Bottom line: ADHD increases susceptibility to premenstrual mood changes, and PMDD can amplify ADHD-related challenges.
What's happening beneath the surface?
HPA-axis (stress hormone) dysregulation
Both ADHD and PMDD involve heightened reactivity in the brain’s stress system (the HPA axis). This can make ordinary stressors feel overwhelming, especially in the premenstrual phase.
Why it matters: When the stress system is more sensitive, emotional and cognitive symptoms may spike just before a period.
Neuroactive steroids and GABA sensitivity
Progesterone rises in the luteal phase and is converted to allopregnanolone, a neurosteroid that usually calms the brain via GABA receptors. In PMDD, GABA receptor responsiveness is altered, causing irritability, anxiety, or emotional intensity.
Women with ADHD, who already have lower inhibitory control, may experience amplified pre-period symptoms.
Why it matters: Reduced GABA responsiveness can intensify anxiety, impulsivity, and emotional reactivity.
Oestrogen, dopamine, and brain-circuit changes
Oestrogen supports dopamine pathways critical for attention, motivation, executive function, and emotional regulation. When oestrogen dips premenstrually, ADHD symptoms such as distractibility, impulsivity, and brain fog often worsen.
Why it matters: Hormonal fluctuations may temporarily lower dopamine availability, worsening ADHD symptoms in the luteal phase.
Serotonin dysregulation
Serotonin helps regulate mood and emotional stability. In PMDD, serotonin signalling is less effective in the luteal phase. Combined with ADHD-related dopamine differences, this can intensify mood swings and impulsivity.
Why it matters: Serotonin sensitivity contributes to the emotional volatility seen when ADHD and PMDD co-occur.
What you can do next (support and treatment options)
1. Talk to a clinician
Discuss symptoms with a GP or mental health professional. Tracking symptoms across at least two menstrual cycles helps clarify patterns and guide diagnosis.
Understand how to talk to your GP about PMDD with our free downloadable guide here.
2. Address co-occurring patterns
Women with ADHD may require support for both attentional symptoms and premenstrual mood changes. Clinicians may consider ADHD medication adjustments or PMDD-specific treatments depending on symptom severity.
3. Explore psychological and behavioural support
Therapies such as CBT, ADHD coaching, or emotion-regulation strategies can help manage the combined effects of both conditions.
4. Lifestyle and self-management strategies
Sleep consistency, balanced meals, regular exercise, structured routines, and stress-reduction techniques can help stabilise both ADHD and PMDD symptoms.
Read more about nutrition for PMDD in our article "Luteal phase nutrition guide" here.
5. Consider multidisciplinary care
Some women benefit from joint support across primary care, psychiatry, and therapy.
Hopeful takeaway: With the right support, women with ADHD and PMDD can experience significant improvements in stability, mood, and daily functioning.
Where to get help
- Speak to your GP about ADHD and PMDD symptoms. They can guide assessment, tracking, and treatment options.
- NHS Talking Therapies (England) or local equivalents can help with mood, stress, and emotional regulation.
- ADHD UK: visit the ADHD UK website for support resources and community guidance
- The PMDD Project: explore the PMDD Project website for advocacy, symptom tools, and education.
Final reassurance: You’re not imagining it. The overlap between ADHD and PMDD is real, understood, and treatable - and help is available.
References:
- Dorani, F., Bijlenga, D., Beekman, A. T. F., van Someren, E. J. W., & Kooij, J. J. S. (2021). Prevalence of hormone-related mood disorder symptoms in women with ADHD. Journal of Psychiatric Research, 133, 10–15. doi:10.1016/j.jpsychires.2020.12.005
- Broughton, T., Lambert, E., Wertz, J., & Agnew‐Blais, J. (2025). Increased risk of provisional premenstrual dysphoric disorder (PMDD) among females with attention-deficit hyperactivity disorder (ADHD): a cross-sectional survey study. The British Journal of Psychiatry, 226(6), 410–417. https://doi.org/10.1192/bjp.2025.104
- Roberts, B. A., Eisenlohr-Moul, T., & Martel, M. M. (2017). Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology, 88, 105–114. doi:10.1016/j.psyneuen.2017.11.015